JPIAMR’s Post

🌍 Join the fight against antimicrobial resistance #AMR! 📢 There are two great opportunities to work with the upcoming European Partnership on One Health Antimicrobial Resistance (OHAMR). The Vetenskapsrådet / Swedish Research Council Council is recruiting: 🔹 Head of Secretariat 🔹 Scientific Adviser If you're interested, we encourage you to apply! More info 👉 https://lnkd.in/dig4qbdC 🔬 Did you know that AMR is one of the top 10 global public #health threats facing humanity? ℹ️ Each year, at least 1.27 million people die of AMR, with #Africa having the world’s highest mortality rate from AMR infections. Addressing this urgent issue is a priority #research area for Global Health EDCTP3, as established by the Strategic Research and Innovation Agenda. Read more about the agenda and our areas of focus here 👇 🔗 https://lnkd.in/d8AvUzBm 🦠 Let's work together to combat antimicrobial resistance and save lives! --------- JPIAMR EU Science, Research and Innovation Africa CDC AMR Action Fund Global Antibiotic R&D Partnership (GARDP) Science|Business European Commission Global AMR R&D Hub EURAXESS Africa The Lancet Elmar Nimmesgern

📣 New publication by Syreon ! We're excited to share our latest publication written in collaboration with experts at Syreon Research Institute on the hidden burden of atopic dermatitis (AD) in Central and Eastern European (CEE) countries. The study, co-authored by Baher ElEzbawy, Zoltán Kaló, Ahmad Fasseeh, András Inotai, Bertalan Németh & Tamas Agh sheds light on the significant yet often overlooked impact of AD, not just on quality of life, but also on productivity and economic resources. Key findings of the study include: The hidden burden of AD varies significantly across the CEE region, contributing up to 0.43% of GDP in some countries. Annually, quality-adjusted life year (QALY) losses due to AD in these countries range between 1,800 to 59,000, resulting in economic impacts of 38 million to 1 billion Euros. The indirect costs, such as productivity losses from absenteeism and presenteeism, amount to 3.6 to 148.9 million Euros per country each year. These findings emphasize that the impact of AD goes beyond the visible symptoms and direct medical costs. Addressing this hidden burden is crucial for enhancing decision-making and prioritizing resources that could significantly improve the quality of life for patients. This research aims to provide healthcare officials and policymakers with the insights needed to make evidence-based decisions regarding the management of AD in the region. Read more about the study and its findings here: https://lnkd.in/dTBWZ87D

I'm proud to be part of this work!! 💪 A new publication in Expert Review of Pharmacoeconomics & Outcomes Research Journal discussing the burden of #Atopic_dermatitis in Central & Eastern Europe. #burden_of_disease #health_economics #Atopic_dermatitis #Syreon

I am pleased to announce that I will be presenting my PhD abstract on Post-trial Care of Research Participants in Phase III Trials in South Africa at the Free State 12th Annual Provincial Health Research Day. Details of the Presentation: Date: 22 November 2024 Time: 14:40 - 14:50 Track: Webinar 6 This exciting program features a diverse range of researchers sharing the outcomes of their work. If you’re interested in attending my presentation, you are welcome to join at the designated time. Access the session here: Join Webinar 6: https://lnkd.in/dQqgPxnr You can also read the abstract on page 61 of the attached program document. Conclusion of the Abstract: Participants should be centred within a seamless continuity of care throughout and beyond a trial, navigated by the investigator-participant relationship, routine health care provision, access to effective drugs through PTA and when registered. PTA primacy neglects the broader goal of seamless continuity of care pre- and post-trial with unclear roles and responsibilities. A framework is needed to improve the situation, supported by clear guidelines and regulations with sponsor inclusion of seamless care in protocols. Further research is needed to optimise the experience of all involved. 

Shout out to Wellcome Trust for a funding application platform that verifies EVERYONE on the team agreed to submit AND for AMAZING support staff, especially PAUL. https://lnkd.in/dhR6ehy2 Paul answered the phone yesterday with our desperate call for help on why parts of our application form were not visible on the platform and kept guiding us every hour until 30 minutes before the deadline when we finally hit the submit button as a team. Orpha Ongiti as lead applicant. Corat Africa brought us together https://lnkd.in/dmJCjSAF On our team the heavy lifting came from Harrison Ndung'u Isaac Ondeche (Mwambogha) Kirika Kivuti Consensus: Even if we are not selected, over the past 6 months of developing the proposal, we have grown as a team and as friends. We will continue this journey together. Seeking Collaborators: Community-Based Health and Citizen Science Research Experts for Sickle Cell Disease Study We just submitted a Wellcome Trust request for funding in partnership with Corat Africa, Africa Nazarene University, Centre for Science and Technology Innovations (CSTI), Masinde Muliro University of Science and Technology, University of The Gambia, The Pathology Network, the UK-Kenya Global Health Innovation Network, Kilimanjaro Christian Medical School, Jimma University, Central Public Health Laboratory, climate change specialists, and health ministries. Call to Action We invite experts in community-based health research and citizen science to collaborate on this groundbreaking research program. Together, we can transform SCD management in East Africa and set a precedent for integrating technology, community engagement, and environmental monitoring to improve health outcomes. Research Title: Climate-Smart Sickle Cell Management in East Africa: Harnessing Citizen Science, AI, and Environmental Monitoring One day we will have fantastic research facility spaces with shared equipment across Africa... Basil O. Malaki Paula K. Davis, EdD, CDE Victor Aprea

😉 Big news!! Our scoping review on orofacial clefts in Africa is finally out! Key findings: 1.     There was a predominance of under-funded descriptive research not indexed by international databases. 2.     Minimal research was directed to population-level OFC preventive programs in primary healthcare settings. 3.     A research agenda is needed to prioritize research needs and secure funds to support South-South collaboration to address the nutrition and feeding-related problems associated with OFCs. It was an interesting experience working under the leadership of Dr. Kehinde Kanmodi, Prof. Dr. Maha El Tantawi, and Prof. Dr. Morenike Ukpong, alongside my colleagues Dr. Nourhan M. Aly and Dr. Sara Atteya, as well as the ExCon and AFRONE team: Dr. Folahanmi T. Akinsolu, Olunike R. Abodunrin, Mobolaji T. Olagunju, Jacob Njideka Nwafor, and Afeez Abolarinwa Salami."

NEW in! #EJPRD and International Rare Diseases Research Consortium (IRDiRC) just published two groundbreaking papers that help pave the way for the future of research data sharing and information governance 1: Getting your DUCs in a row - standardising the representation of Digital Use Conditions https://lnkd.in/gRzs6UBV  2: Common conditions of use elements. Atomic concepts for consistent and effective information governance https://lnkd.in/gBRKj5Hs Together, these publications describe a comprehensive approach to summarizing and managing use conditions for biomedical resources. The DUC schema offers a structured way to collect and standardize information, while the set of common use condition elements ensures consistency and clarity. By assigning permissions and restrictions, and specifying the scope and details of conditions, research activities can be better aligned with institutional missions, funding objectives, and regulatory requirements. More information: https://lnkd.in/gyXgzzkv

New paper published 📘 #openaccess Orphanet Journal of Rare Diseases👇 https://lnkd.in/dGp24rdm In this work (DOI: 10.1186/s13023-024-03161-6), we showed that the number of patients living with an IRD varied between Portuguese regions. 🇵🇹 Using data from national statistics (PORDATA), we observed differences in socioeconomic characteristics between regions. Multiple targeted vision aid and rehabilitation strategies can be developed to ensure that all IRD patients are granted full clinical and socioeconomic support. 🔍 This study can be an example to be replicated in other countries. 🌍 This design allows us to understand which socioeconomic inequalities are present in addition to the visual inequalities already known about these patients. ⚠️ Many thanks to all my co-authors for their invaluable help! ❤️ João Pedro Marques, Cristina Moreira dos Santos, Maria Luisa Coutinho Santos, Sara Vaz-Pereira, José Costa, Pedro Arede, Raquel Félix, Sara Geada, Nuno Gouveia, Rui Silva, Margarida Baptista, Miguel Lume, Ricardo Parreira, Célia Azevedo Soares MD PhD, Maria João Menéres, Carolina Lemos and João Melo Beirão.

Third episode of your favourite ALIMA series, out now 🤩 Revealing the crucial importance of aligning funding for both research and humanitarian efforts

💬 We asked the Spanish State Research Agency (Agencia Estatal de Investigación), a key partner of the Coordination & Support Action BrainHealth, about the expected goal and impact of the future EU Partnership for BrainHealth on research - at both national and EU level. Here's its answer: 🔎 Learn more about the project and its partners: https://lnkd.in/eW7dnXhX 🖋 Share your feedback on the strategic research priorities: https://lnkd.in/eYpM6_W5